Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
The Response Uncovered: Disentangling the Secrets of the Universe- SF Chinatown's historic Empress of China building being revived into cultural campus
- IDF: Staying in West Bank refugee camps will quell lone-wolf terror
- 10 Moving Design Frill for Summer 2023
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
- Israel says it will keep control over part of southern Lebanon after war with Hezbollah ends
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- IDF kills senior PIJ Gaza City Brigade cmdr. who infiltrated Kibbutz Nahal Oz on Oct. 7
